Aclaris Therapeutics Inc reports results for the quarter ended in January - Earnings Summary

Aclaris Therapeutics

07/05/2024 22:01

* Aclaris Therapeutics Inc  ACRS.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -37 cents
to -8 cents per share.
    * Revenue fell 5.1% to $2.40 million from a year ago;
analysts
expected $1.37 million. 
    * Aclaris Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The company reported a quarterly loss of $16.94 million.
    * Aclaris Therapeutics Inc shares had risen by 5.6% this
quarter and gained 24.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $2.00 

This summary was machine generated from LSEG data May 7 at 09:01
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.29          -0.24          Beat
 Dec. 31 2023      -0.34          -0.02          Beat
 Sep. 30 2023      -0.48          -0.41          Beat
 Jun. 30 2023      -0.45          -0.42          Beat